



# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax : 022-2407 3462 / 2407 0144  
Email : admin@aartidrugs.com  
Website : www.aartidrugs.com

AARTI DRUGS LIMITED					
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2014					
(Rs in Lacs except for share data)					
PART I		Quarter Ended			Financial Year Ended
Sr. No.	Particulars	30th June 2014	31st March 2014	30th June 2013	31st March 2014
		(Audited)	(Audited)	(Audited)	(Audited)
1	<b>Income from Operations</b>				
	(a) Gross Sales / Income from Operations	27,877	30,386	23,527	104,435
	Less : Excise Duty & Sales Tax	1,917	2,207	1,668	7,441
	(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	25,960	28,179	21,859	96,994
	(b) Other Operating Income	10	125	5	183
	<b>Total Income from operations (net)</b>	<b>25,970</b>	<b>28,304</b>	<b>21,865</b>	<b>97,178</b>
2	<b>Expenditure</b>				
	(a) Cost of materials consumed	16,709	15,667	13,088	57,082
	(b) Purchase of stock-in-trade	3,195	1,756	2,483	8,602
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,052)	2,383	(577)	569
	(d) Employee benefits expense	872	862	740	3,241
	(e) Depreciation and Amortisation Expense	741	759	669	2,812
	(f) Other expenses	3,261	3,366	3,030	13,046
	<b>Total expenses</b>	<b>22,725</b>	<b>24,793</b>	<b>19,433</b>	<b>85,351</b>
3	<b>Profit from Operations before Other Income, finance costs and exceptional items</b> (1-2)	<b>3,245</b>	<b>3,511</b>	<b>2,432</b>	<b>11,825</b>
4	<b>Other Income</b>	<b>3,245</b>	<b>3,511</b>	<b>2,432</b>	<b>11,825</b>
5	<b>Profit from ordinary activities before finance cost and exceptional items</b> (3+4)	<b>982</b>	<b>917</b>	<b>728</b>	<b>3,349</b>
6	<b>Finance costs (interest)</b>	<b>2,262</b>	<b>2,595</b>	<b>1,704</b>	<b>8,476</b>
7	<b>Profit from ordinary activities after finance cost but before Exceptional Items</b> (5-6)	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
8	<b>Exceptional Items</b>	<b>2,262</b>	<b>2,595</b>	<b>1,704</b>	<b>8,476</b>
9	<b>Profit from Ordinary Activities before Tax</b> (7-8)	<b>539</b>	<b>399</b>	<b>520</b>	<b>2,397</b>
10	<b>Tax Expenses</b>	<b>480</b>	<b>630</b>	<b>440</b>	<b>2,300</b>
	Provision for Taxation - Current	(21)	-	-	-
	- MAT Credit Entitlement	-	(321)	-	(253)
	- Earlier year	80	90	80	350
	Provision for Deferred Taxation				
11	<b>Net profit from ordinary Activities after Tax</b> (9-10)	<b>1,724</b>	<b>2,195</b>	<b>1,184</b>	<b>6,080</b>
12	<b>Extraordinary Items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>92</b>
13	<b>Net Profit for the Period (11+12)</b>	<b>1,724</b>	<b>2,195</b>	<b>1,184</b>	<b>6,171</b>
14	<b>Paid-up Equity Share Capital of Rs.10/- each.</b>	<b>1,211</b>	<b>1,211</b>	<b>1,211</b>	<b>1,211</b>
15	<b>Reserves &amp; Surplus (excluding revaluation reserves)</b>				<b>23,880</b>
16	<b>Earning per share (of Rs. 10 /- each) (not annualised)</b>				
	(a) Basic & Diluted ( before extraordinary items)	<b>14.24</b>	<b>18.13</b>	<b>9.78</b>	<b>50.21</b>
	(b) Basic & Diluted ( after extraordinary items)	<b>14.24</b>	<b>18.13</b>	<b>9.78</b>	<b>50.97</b>

For AARTI DRUGS LTD.

*[Signature]*  
J. Managing Director



# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax : 022-2407 3462 / 2407 0144  
Email : admin@aartidrugs.com  
Website : www.aartidrugs.com

PART II						
A	<b>PARTICULARS OF SHAREHOLDING</b>					
	1	Public shareholding	4,852,768	4,890,428	5,044,288	4,890,428
		-Number of Shares	40.08	40.39	41.66	40.39
		-Percentage of Total Shareholding				
	2	Promoters & Promoter Group shareholding				
	a)	Pledged/Encumbered	Nil	Nil	Nil	Nil
		- Number of Shares	Nil	Nil	Nil	Nil
		-Percentage of shares( as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
		-Percentage of shares( as a % of the total Share capital of the company)				
	b)	Non-encumbered	7,255,782	7,218,122	7,064,284	7,218,122
		- Number of Shares	100	100	100	100
		-Percentage of shares( as a % of the total Shareholding of promoter and promoter group)	59.92	59.61	58.34	59.61
		-Percentage of shares( as a % of the total Share capital of the company)				
		<b>Qtr Ended 30th June' 2014</b>				
B	<b>INVESTOR COMPLAINTS</b>		0			
		Pending at the beginning of the quarter	3			
		Received during the quarter	3			
		Disposed of during the quarter	0			
		Remaining unresolved at the end of the quarter				

**Notes:**

- The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 8th August, 2014
- Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business.
- Figures for the previous period have been regrouped or rearranged wherever necessary.
- The estimated useful lives of fixed assets have been reviewed and revised to align with the provisions of PART C of Schedule II to the Companies Act 2013, effective from April 1, 2014.

Place : Mumbai  
Date : 08/08/2014

For and on behalf of the Board  
For AARTI DRUGS LIMITED

*Harshit M. Savla*  
HARSHIT M. SAVLA  
(JT. MANAGING DIRECTOR)  
DIN : 00005340



**gokhale & sathe**

(regd.)

chartered accountants

308/309, udyog mandir no. 1,  
7-c, bhagoji keer marg,  
mahim, mumbai 400 016

**Auditor's Report on Quarterly Financial Results and Year to Date Results of AARTI DRUGS LTD Pursuant to the Clause 41 of the Listing Agreement**

To

Board of Directors of AARTI DRUGS LTD

We have audited the quarterly financial results of AARTI DRUGS LTD for the quarter ended 30<sup>th</sup> June 2014, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 on Interim Financial Reporting issued under the Companies (Accounting Standard Rules), 2006 which continue to apply under section 133 of the Companies Act 2013 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.





In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 30<sup>th</sup> June 2014.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For GOKHALE & SATHE  
CHARTERED ACCOUNTANTS  
Firm Registration No: 103264W



CA. TEJAS J. PARIKH  
PARTNER  
Membership No. 123215  
Mumbai, Dated: August 8<sup>th</sup>, 2014